165 related articles for article (PubMed ID: 18216299)
41. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
42. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
43. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
[TBL] [Abstract][Full Text] [Related]
44. CD40 mediates downregulation of CD32B on specific memory B cell populations in rheumatoid arthritis.
Zhang X; Burch E; Cai L; So E; Hubbard F; Matteson EL; Strome SE
J Immunol; 2013 Jun; 190(12):6015-22. PubMed ID: 23686494
[TBL] [Abstract][Full Text] [Related]
45. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
46. Systemic Amyloidosis due to Low-Grade Lymphoma.
Wechalekar AD; Chakraborty R; Lentzsch S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1027-1039. PubMed ID: 33099421
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
48. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus.
Su K; Yang H; Li X; Li X; Gibson AW; Cafardi JM; Zhou T; Edberg JC; Kimberly RP
J Immunol; 2007 Mar; 178(5):3272-80. PubMed ID: 17312177
[TBL] [Abstract][Full Text] [Related]
49. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
[TBL] [Abstract][Full Text] [Related]
50. Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.
Abraham RS; Manske MK; Zuckerman NS; Sohni A; Edelman H; Shahaf G; Timm MM; Dispenzieri A; Gertz MA; Mehr R
J Clin Immunol; 2007 Jan; 27(1):69-87. PubMed ID: 17192818
[TBL] [Abstract][Full Text] [Related]
51. [Detection of monoclonal plasma cells in bone marrow and spleen of primary amyloidosis].
Katayama Y; Sakai A; Nobuyoshi M; Shimomura T; Kimura A
Rinsho Ketsueki; 2001 Sep; 42(9):705-9. PubMed ID: 11680983
[TBL] [Abstract][Full Text] [Related]
52. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
53. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
54. Use of an anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: pathophysiology and clinical implications.
Bellotti V; Stoppini M; Perfetti V; Zorzoli I; Marinone G; Invernizzi R; Zambelli LM; Arbustini E; Grasso M; Ferri G
Scand J Immunol; 1992 Oct; 36(4):607-15. PubMed ID: 1411304
[TBL] [Abstract][Full Text] [Related]
55. Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.
Coupland SE; Hellmich M; Auw-Haedrich C; Lee WR; Anagnostopoulos I; Stein H
Br J Ophthalmol; 2005 Mar; 89(3):352-9. PubMed ID: 15722318
[TBL] [Abstract][Full Text] [Related]
56. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.
Perfetti V; Casarini S; Palladini G; Vignarelli MC; Klersy C; Diegoli M; Ascari E; Merlini G
Blood; 2002 Aug; 100(3):948-53. PubMed ID: 12130507
[TBL] [Abstract][Full Text] [Related]
57. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
58. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
[TBL] [Abstract][Full Text] [Related]
59. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
60. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
